Top

06-02-2018 | Rheumatoid arthritis | Review | Article

Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries

Journal: Clinical Rheumatology

Authors: Bassel El Zorkany, Nizar Al Ani, Samar Al Emadi, Jamal Al Saleh, Imad Uthman, Yasser El Dershaby, Mohamed Mounir, Hani Al Moallim

Publisher: Springer London

Abstract

The increasing availability of biosimilar medicines in Middle Eastern regions may provide an opportunity to increase the number of rheumatology patients who have access to traditionally more expensive biologic medicines. However, as well as a lack of real-world data on the use of biosimilar medicines in practice, the availability of intended copies in the region may undermine physician confidence in prescribing legitimate biosimilar medicines. There is a need for regional recommendations for healthcare professionals to ensure that biosimilar drugs can be used safely. Therefore, a literature search was performed with the aim of providing important recommendations for the regulation and use of biosimilar medicines in the Middle East from key opinion leaders in rheumatology from the region. These recommendations focus on improving the availability of relevant real-world data, ensuring that physicians are aware of the difference between intended copies and true biosimilars and ensuring that physicians are responsible for making any prescribing and switching decisions.

The Economist Group (2007) Health care in the Middle East & North Africa summit. http://www.economist.com/sites/default/files/health_care_in_the_middle_east_agenda.pdf. Accessed Sept 2017

Deloitte (2015) 2015 healthcare outlook: Middle East. https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-lshc-2015-health-care-outlook-middle-east.pdf. Accessed Sept 2017

Watad A, Al-Saleh J, Lidar M, Amital H, Shoenfeld Y (2017) Rheumatology in the Middle East in 2017: clinical challenges and research. Arthritis Res Ther 19(1):149. https://doi.org/10.1186/s13075-017-1359-0 CrossRefPubMedPubMedCentral

NHS England (2015) What is a biosimilar medicine? https://www.england.nhs.uk/wp-content/uploads/2015/09/biosimilar-guide.pdf. Accessed Nov 2017

Azevedo VF, Mysler E, Álvarez AA, Hughes J, Flores-Murrieta FJ, Ruiz de Castilla EM (2014) Recommendations for the regulation of biosimilars and their implementation in Latin America. Generics Biosimilars Initiat J 3(3):143–148. https://doi.org/10.5639/gabij.2014.0303.032 CrossRef

Fonseca JE, Gonçalves J, Araújo F et al (2014) The Portuguese Society of Rheumatology position paper on the use of biosimilars. Acta Reumatol Port 39(1):60–71PubMed

Müller-Ladner U, Hong S, Oh C, Taylor P (2015) Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe. Expert Rev Clin Immunol 11(Suppl 1):S5–14. https://doi.org/10.1586/1744666x.2015.1090310 CrossRefPubMed

Azevedo V, Hassett B, Fonseca J et al (2016) Differentiating biosimilarity and comparability in biotherapeutics. Clin Rheumatol 36:2877–2886. https://doi.org/10.1007/s10067-016-3427-2

Montecucco C (2012) Long-term efficacy and safety of biologics in rheumatoid arthritis. Arthritis Res Ther 14(Suppl2):A12. https://doi.org/10.1186/ar3719 CrossRefPubMedCentral

10.

Almoallim HM, Alharbi LA (2014) Rheumatoid arthritis in Saudi Arabia. Saudi Med J 35(12):1442–1454PubMedPubMedCentral

11.

Barhamain AS et al (2017) The journey of rheumatoid arthritis patients: a review of reported lag times from the onset of symptoms. Rheumatol Res Rev 9:139–150. https://doi.org/10.2147/oarrr.s138830

12.

IMS Health (2016) The impact of biosimilar competition. https://wwwimshealthcom/files/web/Market%20Insights/IMS_Health_Impact_of_Biosimilar_Competition_EU_2016pdf. Accessed Nov 2017

13.

Alten R, Cronstein BN (2015) Clinical trial development for biosimilars. Semin Arthritis Rheum 44(6):S2–S8. https://doi.org/10.1016/j.semarthrit.2015.04.002 CrossRefPubMed

14.

US Food and Drug Administration (2017) Biosimilars. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm. Accessed Nov 2017

15.

Scheinberg M, Castañeda-Hernández G (2014) Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice. Arthritis Res Ther 16(6):501. https://doi.org/10.1186/s13075-014-0501-5 CrossRefPubMedPubMedCentral

16.

Yoo DH, Hrycaj P, Miranda P et al (2013) A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 72:1613–1620. https://doi.org/10.1136/annrheumdis-2012-203090

17.

Dorner T, Strand V, Cornes P et al (2016) The changing landscape of biosimilars in rheumatology. Ann Rheum Dis 75:974–982. https://doi.org/10.1136/annrheumdis-2016-209166

18.

European Medicines Agency (2017) Erelzi SmPC. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/medicine/33645. Accessed Oct 2017

19.

European Medicines Agency (2017) Flixabi SmPC. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/medicine/32130. Accessed Oct 2017

20.

Mysler E, Pineda C, Horiuchi T et al (2016) Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatol Int 36:613–625. https://doi.org/10.1007/s00296-016-3444-0

21.

Markenson J, Alvarez DF, Jacobs I, Kirchhoff C (2017) A practical guide about biosimilar data for health care providers treating inflammatory diseases. Biologics Targets Ther 11:13–21. https://doi.org/10.2147/btt.s122335 CrossRef

22.

Barile-Fabris LA, et al (2014) Abstract number 1506. Incidence of adverse events in patients treated with intended copies of biologic therapeutic agents in Colombia and Mexico. American College of Rheumatology. http://acrabstracts.org/abstract/incidence-of-adverse-events-in-patients-treated-with-intended-copies-of-biologic-therapeutic-agents-in-colombia-and-mexico/. Accessed July 2017

23.

Zorkany BE, Alwahshi HA, Hammoudeh M et al (2013) Suboptimal management of rheumatoid arthritis in the Middle East and Africa: could the EULAR recommendations be the start of a solution? Clin Rheumatol 32(2):151–159. https://doi.org/10.1007/s10067-012-2153-7 CrossRefPubMed

24.

Quintiles (2016) Middle East and North Africa. Biosimilars Knowledge Connect http://www.biosimilarsknowledgeconnectcom/biosimilars-by-region/middle-east-and-north-africa. Accessed July 2017

25.

Farhat F, Othman A, el Karak F, Kattan J (2016) Review and results of a survey about biosimilars prescription and challenges in the Middle East and North Africa region. SpringerPlus 5(1):2113. https://doi.org/10.1186/s40064-016-3779-8 CrossRefPubMedPubMedCentral

26.

Al Saleh J, Ragab G, Nash P, Halabi H, Laatar A, el-Sayed Yousef AM, Ehsouna H, Hammoudeh M (2015) Rheumatoid arthritis in the Middle East and Africa: are we any closer to optimising its management? Clin Rheumatol 34(1):1–8. https://doi.org/10.1007/s10067-014-2818-5 CrossRefPubMed

27.

Khraishi M, Stead D, Lukas M et al (2016) Biosimilars: a multidisciplinary perspective. Clin Ther 38(5):1238–1249. https://doi.org/10.1016/j.clinthera.2016.02.023. CrossRefPubMed

28.

Lakhanpal A, Brahn E (2016) Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions. Clin Rheumatol 35(12):2869–2875. https://doi.org/10.1007/s10067-016-3430-7 CrossRefPubMed

29.

European Medicines Agency (2014) Guideline on similar biological medicinal products (CHMP/437/04 Rev 1). London: European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Accessed July 2017

30.

World Health Organization (2009) Guidelines on evaluation of similar biotherapeutic products (SBPs). Geneva: Expert Committee on Biological Standardization. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed July 2017

31.

Abad Hernández MÁ, Andreu JL, Caracuel Ruiz MÁ, Belmonte Serrano MÁ, Díaz-González F, Moreno Muelas JV (2015) Position paper from the Spanish Society of Rheumatology on biosimilar drugs. Reumatología Clínica 11(5):269–278. https://doi.org/10.1016/j.reumae.2015.03.012 CrossRefPubMed

32.

American College of Rheumatology (2016) Position statement on biosimilars. Rheumatology. https://www.rheumatology.org/Portals/0/Files/Biosimilars-Position-Statement.pdf. Accessed Nov 2017

33.

German Rheumatism League (2014) Positionierung der Deutschen Rheuma-Liga Bundesverband e.V.zur Einfuhrung von Biosimilars in Deutschland. Rheuma-liga. https://www.rheuma-liga.de/biosimilars/ Accessed Nov 2017

34.

Danese S, Fiorino G, Raine T, Ferrante M, Kemp K, Kierkus J, Lakatos PL, Mantzaris G, van der Woude J, Panes J, Peyrin-Biroulet L (2016) ECCO position statement on the use of biosimilars for inflammatory bowel disease—an update. J Crohn's Colitis 11(1):26–34. https://doi.org/10.1093/ecco-jcc/jjw198 CrossRef

35.

Egypt Drug Authority (2015) Guidelines for registration of biosimilar products in Egypt. http://www.eda.mohp.gov.eg/Files/774_Guidelines%20For%20Registration%20of%20Biosimilar%20Products%20in%20Egypt.pdf. Accessed Jan 2018

36.

Cheraghali M (2012) Biosimilars; a unique opportunity for Iran national health sector and national pharmaceutical industry. DARU J Pharm Sci 20(1):35. https://doi.org/10.1186/2008-2231-20-35 CrossRef

37.

Feijó Azevedo V et al (2014) Recommendations for the regulation of biosimilars and their implementation in Latin America. Generics Biosimilars Initiat J 3(3):143–148. https://doi.org/10.5639/gabij.2014.0303.032 CrossRef

38.

BRIC Wall (2015) Jordan FDA issues a guideline for the registration of biosimilars. https://bricwallblogwordpresscom/2015/10/05/jordan-fda-issues-a-guideline-for-the-registration-of-biosimilars/ Accessed Nov 2017

39.

Saudi Food and Drug Authority (2017) Guideline on biosimilar products: quality considerations. https://wwwsfdagovsa/ar/drug/resources/DocLib2/Guideline-on-biosimilar-productspdf. Accessed Nov 2017

40.

Republic of Lebanon (2016) Ministry of Public Health. Guidance for registration of similar biological medicinal products (biosimilars) http://wwwmophgovlb/en/view/6917/guidance-and-list-of-requirements-for-registration-of-biosimilars-products Accessed Nov 2017

41.

ASCO website (2017) Pathways to biosimilar approval and market access in Lebanon, South Africa and Brazil. https://amascoorg/pathways-biosimilar-approval-and-market-access-lebanon-south-africa-and-brazil Accessed July 2017

42.

Roshique KK, Ravindran V (2015) Efficacy and safety of a biosimilar rituximab in biologic naïve patients with active rheumatoid arthritis. Clin Rheumatol 34(7):1289–1292. https://doi.org/10.1007/s10067-015-2980-4 CrossRefPubMed

43.

Reinisch W, Smolen J (2015) Biosimilar safety factors in clinical practice. Semin Arthritis Rheum 44(6):S9–15. https://doi.org/10.1016/j.semarthrit.2015.04.005 CrossRefPubMed

44.

Lie G, Sciascia S, Cuadrado MJ (2015) Biosimilar vs biological agents in rheumatology: when are biosimilar agents similar enough? Int Immunopharmacol 27(2):220–223. https://doi.org/10.1016/j.intimp.2015.04.022

45.

International Federation of Pharmaceutical Manufacturers & Associations (2017) Considerations for physicians on switching decisions regarding biosimilars. wwwifpmaorg Accessed July 2017

46.

Egyptian Pharmaceutical Vigilance Center: Ministry of Health and Population (2010) Guidelines for detecting and reporting adverse drug reactions. http://wwwepvcgoveg/guidelines/ Accessed Nov 2017

47.

Broeder AD (2017) SP0144 Biosimilars in rheumatic diseases: society chances versus patient concerns. Ann Rheum Dis 76:35. https://doi.org/10.1136/annrheumdis-2017-eular.7222.

48.

Toussirot E, Marotte H (2017) Switching from originator biological agents to biosimilars: what is the evidence and what are the issues? RMD Open 3(2):e000492. https://doi.org/10.1136/rmdopen-2017-000492 CrossRefPubMedPubMedCentral

49.

Emery P, Vencovský J, Sylwestrzak A et al (2016) Additional efficacy results of SB4 (Etanercept biosimilar) up to week 100: comparison between continuing SB4 and switching from reference Etanercept (Enbrel®) to SB4 [abstract]. Arthritis Rheumatol 68(Suppl 10). http://acrabstracts.org/abstract/additional-efficacy-results-of-sb4-etanercept-biosimilar-up-to-week-100-comparison-between-continuing-sb4-and-switching-from-reference-etanercept-enbrel-to-sb4/. Accessed Jan 2018

50.

Kanters TA, Stevanovic J, Huys I et al (2017) Adoption of biosimilar infliximab for rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel diseases in the EU5: a budget impact analysis using a Delphi panel. Front Pharmacol 8:322. https://doi.org/10.3389/fphar.2017.00322

51.

Centre for Evidence-Based Medicine (2009) Levels of evidence. http://wwwcebmnet/oxford-centre-evidence-based-medicine-levels-evidence-march-2009 Accessed Nov 2017

52.

Joseph J, Solonos M, Michaelides M et al (2017) AB1093 biosimilar infliximab in rheumatology practice—the Cyprus experience. Ann Rheum Dis 76:1437. https://doi.org/10.1136/annrheumdis-2017-eular.4200

53.

Moots R, Azevedo V, Coindreau JL et al (2017) Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. Curr Rheumatol Rep 19(6):37. https://doi.org/10.1007/s11926-017-0658-4

54.

Bae SC, Kim J, Choe J et al (2014) OP0011 a randomized, double-blind, phase 3 equivalence trial comparing the etanercept biosimilar, HD203, with etanercept (Enbrel®), in combination with methotrexate (MTX) in patients with rheumatoid arthritis (RA). Ann Rheum Dis 73(Suppl 2):63–64. https://doi.org/10.1136/annrheumdis-2014-eular.3558 CrossRef

55.

Hillson J, Mant T, Ganguly T et al (2016) Abstract number 605. Assessment of comparative immunogenicity in biosimilar development: immunogenicity and pharmacokinetics following a single dose of M923, a proposed biosimilar for reference adalimumab (HUMIRA®), compared with US- and EU-sourced reference adalimumab in healthy subjects [abstract]. Arthritis Rheumatology 68(Suppl 10). http://acrabstracts.org/abstract/assessment-of-comparative-immunogenicity-in-biosimilar-development-immunogenicity-and-pharmacokinetics-following-a-single-dose-of-m923-a-proposed-biosimilar-for-reference-adalimumab-humira/ Accessed Jan 2018

56.

Endrenyi L, Tothfalusi L (2013) Determination of bioequivalence for drugs with narrow therapeutical index. J Pharm Pharm Sci 16(5):676–682. https://doi.org/10.18433/j31k51 CrossRefPubMed

57.

Yoo DH, Prodanovic N, Jaworski J et al (2017) Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT P13 in the PLANETRA extension study. Ann Rheum Dis 76:355–363. https://doi.org/10.1136/annrheumdis-2015-208786

58.

Park W, Hrycaj P, Jeka S et al (2013) A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 72:1605–1612. https://doi.org/10.1136/annrheumdis-2012-203091

59.

Park W, Yoo D, Miranda P et al (2017) Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis 76:346–354. https://doi.org/10.1136/annrheumdis-2015-208783

60.

Jorgensen K, Olsen I, Goll G et al (2017) Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 389:2304–2316. https://doi.org/10.1016/S0140-6736(17)30068-5

61.

Kay J, Wyand M, Chandrashekara S, et al (2014) Abstract number L20. BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis on stable methotrexate doses: 54-week results of a randomized, double-blind, non-inferiority trial. Arthritis Rheumatology http://acrabstracts.org/abstract/bow015-a-biosimilar-infliximab-in-patients-with-active-rheumatoid-arthritis-on-stable-methotrexate-doses-54-week-results-of-a-randomized-double-blind-active-comparator-study/ Accessed Jan 2018

62.

Schmitz EMH, Benoy-De Keuster S, Meier AJL et al (2017) Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study. Clin Rheumatol 36:2129–2134. https://doi.org/10.1007/s10067-017-3686-6

63.

Abdalla A, Byrne N, Conway R, Walsh T, Mannion G, Hanly M, O’Sullivan M, Curran AM, Carey JJ (2017) Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product. Rheumatol Res Rev 9:29–35. https://doi.org/10.2147/oarrr.s124975

64.

Tweehuysen L, Huiskes V, Bemt BVD et al (2017) FRI0200 higher acceptance and persistence rates after biosimilar transitioning in patients with a rheumatic disease after employing an enhanced communication strategy. Ann Rheum Dis 76:557. https://doi.org/10.1136/annrheumdis-2017-eular.2889

Medicine Matters Rheumatology

Abstract